Vanda Pharmaceuticals (VNDA) EBITDA (2010 - 2026)

Vanda Pharmaceuticals has disclosed EBITDA across 17 years of filings, most recently posting -$50.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$50.0 million, down 22.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$159.2 million (down 122.6% YoY), and the FY2025 annual result was -$150.1 million, down 277.43% from the prior year.
• EBITDA came in at -$50.0 million for Q1 2026 at Vanda Pharmaceuticals, down from -$40.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $6.9 million in Q4 2022 to a low of -$50.0 million in Q1 2026.
• The 5-year median for EBITDA is -$9.0 million (2024), against an average of -$14.4 million.
• Across the five-year window, EBITDA soared 131.24% in 2023 and sank 493.42% in 2024, its largest moves.
• Vanda Pharmaceuticals' EBITDA stood at $6.9 million in 2022, then sank by 199.9% to -$6.9 million in 2023, then slumped by 45.41% to -$10.0 million in 2024, then slumped by 299.81% to -$40.0 million in 2025, then decreased by 24.72% to -$50.0 million in 2026.
• The last three EBITDA figures came in at -$50.0 million (Q1 2026), -$40.0 million (Q4 2025), and -$31.0 million (Q3 2025), per Business Quant data.